Twist Bioscience (NASDAQ:TWST) Trading 8% Higher

Twist Bioscience Co. (NASDAQ:TWST)’s share price was up 8% during mid-day trading on Tuesday . The stock traded as high as $31.81 and last traded at $31.81. Approximately 105,794 shares changed hands during mid-day trading, a decline of 88% from the average daily volume of 907,955 shares. The stock had previously closed at $29.45.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on TWST shares. Barclays dropped their price objective on shares of Twist Bioscience from $45.00 to $40.00 and set an “overweight” rating for the company in a research report on Wednesday, April 10th. Scotiabank increased their price objective on shares of Twist Bioscience from $30.00 to $43.00 and gave the stock a “sector outperform” rating in a research report on Monday, February 5th. Finally, The Goldman Sachs Group raised shares of Twist Bioscience from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $25.00 to $45.00 in a research report on Wednesday, January 17th.

Twist Bioscience Trading Down 2.4 %

The stock’s fifty day moving average is $35.15 and its two-hundred day moving average is $30.32.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Friday, February 2nd. The company reported ($0.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.03. The business had revenue of $71.50 million during the quarter, compared to analyst estimates of $67.59 million. Twist Bioscience had a negative net margin of 78.44% and a negative return on equity of 32.16%. The business’s revenue was up 31.8% on a year-over-year basis. During the same period last year, the business earned ($0.74) EPS. Equities analysts anticipate that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Insider Activity at Twist Bioscience

In related news, Director Robert Chess sold 4,110 shares of the firm’s stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the completion of the sale, the director now directly owns 64,169 shares of the company’s stock, valued at approximately $2,244,631.62. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other Twist Bioscience news, Director Robert Chess sold 4,110 shares of the stock in a transaction on Thursday, February 8th. The shares were sold at an average price of $34.98, for a total transaction of $143,767.80. Following the transaction, the director now directly owns 64,169 shares in the company, valued at approximately $2,244,631.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Emily M. Leproust sold 1,128 shares of the stock in a transaction on Wednesday, March 20th. The shares were sold at an average price of $33.52, for a total transaction of $37,810.56. Following the transaction, the chief executive officer now owns 515,281 shares in the company, valued at $17,272,219.12. The disclosure for this sale can be found here. In the last three months, insiders sold 11,037 shares of company stock valued at $384,092. Corporate insiders own 3.92% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new position in Twist Bioscience during the 4th quarter valued at $526,000. Seven Eight Capital LP lifted its position in shares of Twist Bioscience by 154.2% in the 4th quarter. Seven Eight Capital LP now owns 38,420 shares of the company’s stock worth $1,416,000 after buying an additional 23,305 shares during the last quarter. Evoke Wealth LLC bought a new position in shares of Twist Bioscience in the 4th quarter worth about $572,000. Artisan Partners Limited Partnership lifted its position in shares of Twist Bioscience by 111.3% in the 4th quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after buying an additional 1,961,621 shares during the last quarter. Finally, Chesapeake Capital Corp IL bought a new position in shares of Twist Bioscience in the 4th quarter worth about $493,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.